Myriad Genetics Files 8-K: Officer/Director Changes & Financials
Ticker: MYGN · Form: 8-K · Filed: Aug 18, 2025 · CIK: 899923
| Field | Detail |
|---|---|
| Company | Myriad Genetics Inc (MYGN) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01, $490,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election, financial-statements
Related Tickers: MYGN
TL;DR
MYGN 8-K: Leadership shakeup and financial updates filed.
AI Summary
Myriad Genetics, Inc. filed an 8-K on August 18, 2025, reporting events as of August 15, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in directors or officers can indicate internal shifts that may affect company strategy or performance.
Key Players & Entities
- MYRIAD GENETICS INC (company) — Registrant
- August 15, 2025 (date) — Date of earliest event reported
- August 18, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 87-0494517 (ein) — IRS Employer Identification No.
- 322 North 2200 West Salt Lake City, Utah 84116 (address) — Principal executive offices
- ( 801 ) 584-3600 (phone_number) — Registrant's telephone number
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, but the specific names and details are not provided in this summary section of the 8-K.
What is the nature of the compensatory arrangements mentioned?
The filing states that there are compensatory arrangements of certain officers, but the specific details of these arrangements are not elaborated upon in the provided text.
When was this 8-K report filed?
The 8-K report was filed on August 18, 2025.
What is the principal executive office address for Myriad Genetics, Inc.?
The principal executive offices are located at 322 North 2200 West, Salt Lake City, Utah 84116.
What is the SIC code for Myriad Genetics, Inc.?
The Standard Industrial Classification (SIC) code for Myriad Genetics, Inc. is 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 1,075 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2025-08-18 08:31:42
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
- $490,000 — r will be paid an annual base salary of $490,000. Mr. Wheeler will be eligible to receiv
Filing Documents
- mygn-20250815.htm (8-K) — 34KB
- ex-991myriadgeneticspressr.htm (EX-99.1) — 10KB
- imagea.jpg (GRAPHIC) — 33KB
- 0000899923-25-000089.txt ( ) — 232KB
- mygn-20250815.xsd (EX-101.SCH) — 2KB
- mygn-20250815_def.xml (EX-101.DEF) — 14KB
- mygn-20250815_lab.xml (EX-101.LAB) — 25KB
- mygn-20250815_pre.xml (EX-101.PRE) — 15KB
- mygn-20250815_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
ITEM 7.01 Regulation FD Disclosure. A copy of the press release announcing Mr. Leffler's departure and Mr. Wheeler's appointment as Chief Financial Officer and principal financial officer on the Commencement Date is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated Aug ust 18, 2 025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: August 18, 2025 By: /s/ Benjamin Richard Wheeler Benjamin Richard Wheeler Chief Financial Officer